amp;'0(5,-(4@1,A9$0(B$-9320C(6&1%-&'(D9''0-(40''(E+F306DGH…; >"4(?%?B A2*#$(0$,,8 04#9E*-$(C-2"-<$D; />A78?>L!K;.;7E ?7C)!6;E9 >H8GC.;>6." /> amp;'0(5,-(4@1,A9$0(B$-9320C(6&1%-&'(D9''0-(40''(E+F306DGH…; >"4(?%?B A2*#$(0$,,8 04#9E*-$(C-2"-<$D; />A78?>L!K;.;7E ?7C)!6;E9 >H8GC.;>6." /> amp;'0(5,-(4@1,A9$0(B$-9320C(6&1%-&'(D9''0-(40''(E+F306DGH…; >"4(?%?B A2*#$(0$,,8 04#9E*-$(C-2"-<$D; />A78?>L!K;.;7E ?7C)!6;E9 >H8GC.;>6." />

Immunitybio, Inc. · NASDAQ:IBRX

Immunitybio — 39th Annual JP Morgan Healthcare Conference 2021

35 slides from Immunitybio's conference presentation, Jan 13, 2021

  1. Slide 1: 39th Annual JP Morgan Healthcare Conference

    39th Annual JP Morgan Healthcare Conference January 13, 2021 NantKwest, Inc. & ImmunityBio, Inc. – Presented at 39th Annual JP Morgan Healthcare Conference – January 13, 2021 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements relating to the proposed transaction involving NantKwest, Inc. (“NantKwest”) and ImmunityBio, Inc. (“ImmunityBio”), including financial estimates and statements as to the expected timing, completion and effects of the p

  3. Slide 3: ! A&&$*$%$&+%/&*.$(//%/0*%/,&7'%#9.* ! AB3#0.&91#'2.01#-.*,$.2(,&%*9#2.7.2%(; ! C&1.D(+&/,9+#E1'%9*.(%/*#/$#01.5#$,'%/*#

    !"#$%&'()*##+&",-'./01)23/,4".#5) 6',,'.)2"5%,%"&'(),")7.'/,)2/,%'&,5 B1&91F/ )*4546/3'!"#$"%&'789: !"#$"%&'!( )*+,-./01'2/03 ! ="#(:*"(/0&*%--9/#'2&"($)* !"#$%&#"'$()*+$,*-$(*-( ! !"#$"%&'(")*!"#$%"&'()&&*%'+!(,' $"#:97'.*.$(//%/0*".#)/012' ./(0$,,(12$3"+4(5(678*9-()39#$*-8 -*&& $+(',#"-.*.$(//%/0*

  4. Slide 4: !"#$%&'($)*+#,-*.*+//0#1$2314)*+#,-*5 67'('#$'8*"$*9: !" ;##0"<*=6*>47?"#*@'"<$A,"7'*B4#C'7'#,'*5 ="#0"72*D9)*EFED Y

    !"#$%&'($)*+,-#-.",,/*012"#.'1*!%*+',,*3,"$4567 !"#$"%&'!( ! !"#$"%&'(")*!"#$%"&'()&&*%'+!(,' -*&& $+(',#"-.*.$(//%/0*#,,1'2&1 .2&+,*34156*7&++*+%/&*8*(9'#+#0#9.* 8*(++#0&/&%7*.'&-*7&++*$"#:97'. ! !2(.&*6*7+%/%7(+*'"%(+. ! !"#$"%&'(")*-(/9,(7'9"%/0* $"#7&..&.*(/:*;<!*+("0&*.7(+&* ,(7%+%'%&. !""#$%&'

  5. Slide 5: NantKwest: Clinically Advanced NK Cell Platform

    NantKwest: Clinically Advanced NK Cell Platform aNK PD-L1 CD-19 HER2 EGFR haNK (NK-92) t-haNK t-haNK t-haNK t-haNK Innate Immunity Without NKG2D NKG2D NKG2D NKG2D NKG2D NKG2D NASDAQ: NK Major Inhibitory Receptors ü Proprietary Natural Killer (NK) High-Affinity CD16 X CD16 CD16 CD16 CD16 CD16 cell pl

  6. Slide 6: @56*<"!%*"#1*3AB8C*$B<"!%*

    !"#$%&'($)*8"69'*:.",'*+',,*;<'6"=/*>"#?4".$?6-#9*+"=".-$/ @56*<"!%*"#1*3AB8C*$B<"!%* !""#$%&#'%&("#)*$+,*(#-.((&,#/&((0#*0#*#1,23+4$5# 6&*3.78#1,23+4$.27#*73#97"+0.27#2"#)-:;<#=78.7&&,&3#/&((0 !"#$%&"'&()*$$ !"#$%&"'&+,-*' !"#$"%&'!( .//0%120312)/&4*%,#*)&5"))2#&(2))$ ! !"#$"%&'(")*!"#$%"&'()&&*%'+

  7. Slide 7: ?%C7"# F;(/D%*1#R*&%2+15 J.(,&.0#N%001&

    ?%C7"# 6071(80$0-&19,$(8+*(9$(&(:,7 F;(/D%*1#R*&%2+15 J.(,&.0#N%001& :9,',.93(+&$%5&31%-9$.(;0<930(5,-(6=> +>6>A8+7A;S7L8"# 3?*%;6%!%T>U "G"V%J, "G"V%OO- !""#$%&'()*+,-.%)&/%01% .1+(01$( 201$13*0-4+5*&(6 20%61$7 !"#$%&'($)*+#,-*.*+//0#1$2314)*+#,-*5 67'('#$'8*"$*9:!" ;##0"<*=6*>47?"#*@'"<$A,"7'*B4#C

  8. Slide 8: ?&19,$&'0(5,-(4@1,A9$0(B$-9320C(6&1%-&'(D9''0-(40''(E+F306DGH 4@1,A9$0FI$C%30C(+0J,-@F'9A0(6&1%-&'(D9''0-(40''K(B729L…

    ?&19,$&'0(5,-(4@1,A9$0(B$-9320C(6&1%-&'(D9''0-(40''(E+F306DGH 4@1,A9$0FI$C%30C(+0J,-@F'9A0(6&1%-&'(D9''0-(40''K(B729L91(B$2&$30C( ?0KM,$K0K(#.&9$K1(+@0',9C(N0%A0J9&(9$(*-0F4'9$93&'(+,C0'K :;8#3"<#= !"#$%"& '(&&)% *!+, -)&&. "%) "/ )0)%1(/1 -)&&$&"% (00$/2#3)%"45 62% 4"#()/#. 7(#3 "-$#) 05)&2(8 &)$')

  9. Slide 9: >"4(?%?B A2*#$(0$,,8 04#9E*-$(C-2"-<$D

    8+,"3"9"+5):)833"9'&'%;<)=>;'?@ !"#$%&'(&)$*+,"'-,./,0"1'2/)3%/4'5+44"%'("44'64/)7$%# >"4(? >"4(? >"4(? >"4(?@ >"4(?@ F&;/7&1'1&6.(%/* O/&#O,(,&1#M'1' #$%&'(")'$*+,- .,/"0%/$123(%- >"4(?%?B JN#R*&%2+-1*( B9'#+#0#9.*B$2&"&.%. B9'#+#0#9.* B+%J9#'*K/&*=(0* ;<!1%/1(1=#I D#/7&/'"('& B9'#+#0#9.*D)'#@%/&*

  10. Slide 10: 6&$1DO0K1(*'&15,-JKH(

    6&$1DO0K1(*'&15,-JKH( -./0%&'1&2034#.'5#%467.8'9"2$%":';4::.%'1.::<'=->6.9;? @'-.<.#67&/":'A2./'1.::<'=-A1? ?%C7"# F;(/D%*1#R*&%2+15 J.(,&.0#N%001& ;0$4<4?40( c>6I1#I"I34P .*"<<4?'#'1, U4#47( ?M/ ?%C7"# .=+"(">"=7?@?.((">%-%)* 34#'*>"774&) 6'71HA'7"<*3<448 A%1"&B?8B+"C)-%?D-&)*3%/?'+%1?8%((7 B478*G1

  11. Slide 11: />A78?>L!K;.;7E ?7C)!6;E9 >H8GC.;>6

    D77?#-$/E-5)*!%F*;*+',,*"#1*>".65=<"9'*3,"$4567( :-#*;9D4(04#9E*-$( :,;7I*-%J97-D L"<<*-$ 678*9-()39#$*-8 KII7-9%G9D7,"#938 1$<2-9,9'*$8 />A78?>L!K;.;7E )*+,-./01'2/03 ! ="#(:*"(/0&*%--9/#'2&"($)* $"#:97'.*.$(//%/0*".#)/012' 3$4)0.'5%0#*).46')77$.*8 701$&"#0%4 (/:*"1*.09)%$4 $+(',#"-. GC.;S!.;6F V:9

  12. Slide 12: ?7C)!6;E9 >H8GC.;>6 />A78?>L!K;.;7E

    G#="6",,','1*+57H-#'1*D77?#5$<'6"=/*3,"$4567( :-#*;9D4(04#9E*-$( :,;7I*-%J97-D L"<<*-$ ."#73",(/*,,$3 678*9-()39#$*-8 KII7-9%G9D7,"#938 1$<2-9,9'*$8 />A78?>L!K;.;7E GC.;S!.;6F V:9>A;C;L!K ?79>A< [HH%.)7%M)7KH8"#8/7KKE "#8Z8V8/7KKE ?!CA>D)!F7E V8/7KKE G:.>K>F>:E8?79>A<8C7"# ,7!L G6W.;S!8$"%XOR( GKL>U

  13. Slide 13: Late Stage Clinical Development: Anktiva

    Unparalleled Combined Platforms Across Oncology and Infectious Disease ImmunityBio ImmunityBio ImmunityBio NantKwest Phase Target Indication Pre-clinical Ph I Ph II Ph III Fusion Proteins Aldoxorubicin Adenovirus Natural Killer II / III BCG Unresponsive NMIBC Breakthrough & Fast Track ✓ Anktiva Late

  14. Slide 14: Significant Market Opportunity for Lead Programs

    Significant Market Opportunity for Lead Programs BLADDER LUNG PANCREAS COVID-19 BCG Unresponsive Non-Muscle Non-Small Cell Lung Cancer Pancreatic Cancer SARS-CoV-2 Invasive Bladder Cancer 1L Squamous & Non-Squamous 3L Metastatic COVID-19 Vaccine NSCLC Pancreatic Cancer ~81k ~106k ~31k ~350mm Bladder

  15. Slide 15: Selected Summary of Upcoming Catalysts

    Selected Summary of Upcoming Catalysts Ph Trial Clinical Update Anticipated Timing • Full Accrual • Q4 2020 II / III BCG Unresponsive NMIBC Carcinoma In-Situ (CIS) 2L • Initial Readout for FDA • 1H 2021 Bladder • Anticipated BLA Filing • 2H 2021 • Full Accrual • Q4 2021 II BCG Unresponsive NMIBC Pap

  16. Slide 16: B#324C"'=DE>(F? V:9>A 0>N W 1(0$,,

    !"#$%&'()*+,-./(0123'"%45(67(!2$%6" B#324C"'=DE>(F? +23.4)56789:,&"$;# G;DEHOP$4)%"12/(.#O9/#(?285OC5#2'(/)OQ$.(2/OR%2#)(/ !"#$%&'()<(#&=$"8)/6;$&")>9&#8$" G"<39+2"'$8 Cytokine 17I93 /+I` Cytokine Fusion G;DEH!SFTO"/8OG1UEOQ-O V:9>A #"%1)#>O"-#(="#)O"/8O4%2&(6)%"#)O )/821)/2$.O'(&&(/1O-)&&.O!+>O !"#

  17. Slide 17: AB'.B%'C)"4)?"&>=+5;3')*&B/5%B')63/(('.)!/&;'.)D?=*6!E A77$.)#2E)0X4 ;55%0"-M

    AB'.B%'C)"4)?"&>=+5;3')*&B/5%B')63/(('.)!/&;'.)D?=*6!E TK!LL7A ,:6F TA7!E. *!6CA7!E /[^5+ R)JM'%"#*4'03'5%0J%*44)0.'".1'%*-$%%*.-* ,#"*3<O=D*-(@&*%'*#/&*#,*'2&* 05^ 704#'*S5*.4)9*'-".-*% '#*'"&(' :#".1"%1'03'="%* D9""&/'*.'(/:(":*#,*'"&('-&/'*%.*P"(/.9"&'2"(+*%*4*-#)0.'03'/&"11*%'#$70% =$%%*.#' UPQV

  18. Slide 18: 3<"('*D*K'(?,$(*-#*!>DE+

    TK!LL7A ,:6F 3<"('*D*K'(?,$(*-#*!>DE+ TA7!E. *!6CA7!E /[^5+ 8,*)+9/ : ;(< +, =+>.?@+A* 2!B;( C 6./A" B @"A34)A 05^ +>E788 <*450.4* ;44*447*.#4 C1$&)*>(613#0*)-- *!.;76. M.!F7 !"#$%&'()*+$ =-' I? &? -'? -Y? -X? '-? !"# 1$6&100*&1%$D !',)$-&'./$ ! 3.7 Q! /2c /2 /2 /2 /2 /2 /2 /2 "*,0%(')01($)1$ HEE [0

  19. Slide 19: E+MBG#6'(=5#(-2'*!>DE+*!"# !*S#':#*54

    TK!LL7A 3<"('*DD*L*DDD*A"$"*-#* E+MBG#6'(=5#(-2'*!>DE+*!"# ,:6F TA7!E. *!6CA7!E W/12(/1OP#$85 /[^5+ )3*I"34(C-D+9*-#(X(C204&)#)OM).42/.)O"#O9/5OV(0) &$<9-D"34(C-D+9*-#(X((T$%"#(2/O26OC204&)#)OM).42/.) 05^ R%(0"%5OX/842(/#YOCMO"#O"/5O#(0)>O A9"('%#/*#,*DV*('*C?'70.#M4' 7(#3O&27)%O?2$/8O26OZH[OCGO\OF]

  20. Slide 20: #,'=5<>?4@AB@C'%,D'E#.+86#$%F'28G7%6#.8,'+8'H*&+6ID%

    TK!LL7A ,:6F !""#$%$&'(')%"*+&'#,'-%+#*,+.'/#+0'12345,6*.78,.#9*':;<12'2<) TA7!E. #,'=5<>?4@AB@C'%,D'E#.+86#$%F'28G7%6#.8,'+8'H*&+6ID% *!6CA7!E S77&/615#_.*#4=4= /[^5+ 05^ /CS.Q1C%[U@ \MK!1%W][WY CTT*<"<4(C-D+9*-#8 /$4#37D" :-E#*^"(_(J0R =<'<"#*'+DTV'=A, B'*(/)*'%-&*#"*?*-#/'2. Z?V *^E[>OHF[, @?V *H

  21. Slide 21: -0%.*'<<J'K%+%'#,'>I,L'2%,$*6' C +& %,D'@ #& >#,*':)2>2'M=5<>?'@ABNNO .$c#(&#$+8

    TK!LL7A -0%.*'<<J'K%+%'#,'>I,L'2%,$*6' ,:6F TA7!E. C+& %,D'@#& >#,*':)2>2'M=5<>?'@ABNNO D#'G4<6$<<40#<'H427'E$#I>-BJ *!6CA7!E /[^5+ 05^ G7,#*%09293#(J"8E$#("-D(&#"#78 )"#*$-#8(O$<$*^*-'(02$<E+9*-#(_(:-E#*^" M)>dE DA7K;9;6!A< 7S;L76C7 >H K>6F%.7A9 E.!BK7 L;E7!E7 ;6 ', e R, "M/,/ c dLG;VO^B]HHO(.O"/O2

  22. Slide 22: P,Q+#9%'%.'+0*'1%$QJ8,*'+8'20*$Q78#,+'?0*6%7&'R*L#.+6%+#8,%F'?6#%FS' P,Q+#9%'T'20*$Q78#,+'#,'U#6.+'>#,* >I,L'2%,$*6'M…

    TK!LL7A P,Q+#9%'%.'+0*'1%$QJ8,*'+8'20*$Q78#,+'?0*6%7&'R*L#.+6%+#8,%F'?6#%FS' ,:6F P,Q+#9%'T'20*$Q78#,+'#,'U#6.+'>#,* >I,L'2%,$*6'M=5<>?'CABC@O TA7!E. 53,7% I,&>%+?0-/)*,+)"- 5&%J*()-)*,( 53 0 53?00 53?000 4=7)"-?5&"+%)-7 .(/"G"&=K)*)- ./%-"L)&=7 !,+=&,(?M)((%& *!6CA7!E +++ IJ'#KE-C4E6'L'!4=D#KE-C4E6

  23. Slide 23: "7U.8M.7DE

    TK!LL7A P-9M'0(60.&19<0(:-0&K1(4&$30-(*2&K0(ILQII ,:6F B2D'E+4+,>'F&'GH'IJIH'7$%'@/,1$#+K"1'6./A"'L +,'M2;( TA7!E. *!6CA7!E !".#(W*4#'OM"4*'C/'Q'?'b!E='B"#"'+?(4 I).*'0%'F%*"#*%, /[^5+ S7&%0#4=4= @<<Z _YV !"# 05^ H*1)".'O^:Z' C`aP'70.#M4 CEFGD-H#IJ(3&6-K1&'- H*1)".'@:Z' ?Ua?'70.#M4 <16(*6(-2%$&)%0 P

  24. Slide 24: NantKwest, ImmunityBio Announce Positive Interim Data in Pancreatic Cancer

    January 13, 2021 NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no

  25. Slide 25: $%&'()(*+,-.(+,.+F+)$%'N89"43#/FO'+,'!")/A)/)+0'6/,0%"/)+0'(/,0"% !"1+/,'P9"%/44'Q3%9+9/4'RSJ'!$,).A *!.;76.E8$' &- ,…

    TK!LL7A $%&'()(*+,-.(+,.+F+)$%'N89"43#/FO'+,'!")/A)/)+0'6/,0%"/)+0'(/,0"% ,:6F !"1+/,'P9"%/44'Q3%9+9/4'RSJ'!$,).A TA7!E. *!6CA7!E ?(4 I).*'0%'F%*"#*%'H*#"4#"#)-'O".-%*"#)-'=".-*% /[^5+ H 05^ 6 ? M"!('f'OB8IC'A.M)/)#0%'+;9*&$7"/, \ <&:%(/*KM&"(++*R9"M%M(+*f*^FE*-#/'2. *!.;76.E8$'&- ,;678>A83A7!.7A( 3

  26. Slide 26: *+,-.(/,$%&'(E/9$%/F4"')$'./25':'6D?TH'+,.+F+)$%'N89"43#/FO'+,'!")/A)/)+0'6/,0%"/)+0'(/,0"% !"1+/,'P9"%/44'Q3%9+9/4')…

    TK!LL7A *+,-.(/,$%&'(E/9$%/F4"')$'./25':'6D?TH'+,.+F+)$%'N89"43#/FO'+,'!")/A)/)+0'6/,0%"/)+0'(/,0"% ,:6F !"1+/,'P9"%/44'Q3%9+9/4')$'D/)"'N8A'$7'U/,'IJIJO'2$)'@"/0."1 TA7!E. *!6CA7!E B6L E0(*$1&$F&*')*&$D*)',)')0.$7'(.&*')0.$G'(.*& /[^5+ 05^ O"#)*.#4'+?(4 I).*'0%'F%*"#*%, ;<1K' =>?@A#(?),78 <&:%(/*KM

  27. Slide 27: )2"8$(Y(13*",(9T()>%!?(#%2"./(*-( 09I;*-"#*9-(b*#2(02$I9( KII7-9I9D7,"#*9-(*-(:D^"-<$D(

    TK!LL7A !"#$%&'#()*+&!"#$%&'"(&&)*'&'+),-./'*"/*"0'1-,,2"3+4-*1%+"'5" ,:6F 6%.-7.-./1"8-*15%-./1"#-*1%5"9:;(0<=>>? TA7!E. S2(%610;#R*&/00%*9 *!6CA7!E B"#"'"4'03'g".'?U?CZ )2"8$(Y(13*",(9T()>%!?(#%2"./(*-( H^*(77"9&:*'#*:('&*%/*?/C L%/&*#"*;"&('&"*UR%/0+&*B"-W*G D#2#"'*D /[^5+ 09I;*-"#*9-(b*#2(02$I9(

  28. Slide 28: D77?#-$/E-5N(*+JODABCP*O"..-#')*

    TK!LL7A ,:6F D77?#-$/E-5N(*+JODABCP*O"..-#')* TA7!E. *!6CA7!E $%&'(#)*+,-./(0(1)23#4 /[^5+ 05^ O--9/%')=%#h.*6/:*0&/&"('%#/*$+(',#"-*2B:Z*%.*h)77$.0&0J)-"&&2'K$)*#i' @%"&'9"--).*'033*%4'$.)K$*'"19".#"J*4'-075"%*1' #0'0#M*%').j*-#)0.8/"4*1'9"--).*4').'1*9*&057*.# &/(T+%/0*%--9/&*"&.$#/.&*&M&/*%/*'2&*

  29. Slide 29: 2#CR(SFT%K9,$(U(6FBPS;(4VWI;F>"(W&339$0

    TK!LL7A ,:6F 2#CR(SFT%K9,$(U(6FBPS;(4VWI;F>"(W&339$0 TA7!E. M(-TTV8((B2- *!6CA7!E /[^5+ 345/*650-7"4/02-"8-9&1*+*2/#%/*"+-"8-.:;-<%==*+0->"+2/#4=/-/"-9=?*0@0-A->055-30&*%/0&-B-34="2%5-C114+*/D 05^ "9,4&:;)&<=>'*?/8&>#@@AB% +S5@#8eJ#FPTUE)!V#T.22%*1 +S5@#8eJ#FPTUE)!V#T.22%*1 &7;<7#"-$978(FY%N°0H Q3",

  30. Slide 30: 28G7F*+*'<,0#J#+#8,'8"'V#6%F'R*7F#$%+#8,'#,':%.%F'('>I,L'-%..%L*. U8FF8/#,L')IJ$I+%,*8I.'M-6#G*O'('W6%F'M188.+O'V%$$#…

    ',)8,9(:;$<,/- 28G7F*+*'<,0#J#+#8,'8"'V#6%F'R*7F#$%+#8,'#,':%.%F'('>I,L'-%..%L*. &/0$1 &/0$2 &/0$3 &/0$4 &/0$5 &/0$6 &/0$7 TK!LL7A # '()* ./"*)& !"2/++ # 3*4()* %,$1-./5 &,#0-./5 #,//-./5 #,22-./1 +,1%-./1 5,+$-./1 2,%+-./1 ,:6F U8FF8/#,L')IJ$I+%,*8I.'M-6#G*O'('W6%F'M188.+O'V%$$#,%+#8, +0*)),12, ',)

  31. Slide 31: 891,:;%"%2';(<(:;%"%2';(=>?19%1"21(%"(@*A NKO'($G50(0.'5$LM3*&0*(.* 7&*AG50(0.'5$LM3*&0*(.*

    891,:;%"%2';(<(:;%"%2';(=>?19%1"21(%"(@*A TK!LL7A ,:6F TA7!E. *!6CA7!E /[^5+ 7&*AG50(0.'5$LM3*&0*(.* NKO'($G50(0.'5$LM3*&0*(.* 05^ )N-6/'I'>0+=+B-0'T*+-0'F='i'eG >4C50/./3'O]Ib !>T]OIYI]Yb )N-6/'O'>0+=+B-0'T*+-0'F='i'IUG )0-==/3'#.-*.'%O'O]OI !>T]cU]UU]I A-B-KE/'"=+C-0'#.E31'D f-=E-*1'O]O] @-.'*6(-P

  32. Slide 32: Closing

    Closing NantKwest, Inc. & ImmunityBio, Inc. – Presented at 39th Annual JP Morgan Healthcare Conference – January 13, 2021 32

  33. Slide 33: Q-9<,/*RS='6-'#.'1*>"#"9'7'#$*;'"7*&-$<* 3652'#*;6".I*K'.561

    Q-9<,/*RS='6-'#.'1*>"#"9'7'#$*;'"7*&-$<* 3652'#*;6".I*K'.561 *!.A;CW8M>>6%M);>6Ff8?+ 2;C)8GLC>CWf8?TG +!S;L8M!C)Ef8?TG ,766;78M76L7Af8?+ T>BB<827LL<f8?+ 4!B;>8T767L7..;f8?+8 !"#$%&'(#)*+,'-.,/ *+'#0)!"#$%&'(#)300'$#- *+'#0)1'/,/$',2)300'$#- *+'#0)39#-,&'/:)300'$#- *+'#0)7#8'$,2)300'$#- *+'#0);&-,&#:

  34. Slide 34: ;6"#(".$-5#*A'$"-,(*T*!'S$*:$'=(* 1$3I8 09-8*D$3"#*9-(

    ;6"#(".$-5#*A'$"-,(*T*!'S$*:$'=(* /$4(13"-8"<#*9-( ] NI72(/0& "('%# #, Ua[CD .2("&. #, 3(/'4X&.' ,#" &M&") .2("& #, O--9/%')=%# 1$3I8 ] K/ ( ,9++) :%+9'&: T(.%.S O= .2("&2#+:&". X%++ #X/ kY?V (/: 34 .2("&2#+:&". X%++ #X/ k?[V #, '2& 7#-T%/&: 7#-$(/)F 09-8*D$3"#*9-( ] HEE` .'#7@1,#"1.'#7@ -&"0&" G*c

  35. Slide 35: ! A&&$*$%$&+%/&*.$(//%/0*%/,&7'%#9.* ! AB3#0.&91#'2.01#-.*,$.2(,&%*9#2.7.2%(; ! C&1.D(+&/,9+#E1'%9*.(%/*#/$#01.5#$,'%/*#

    !"#$%&'()*##+&",-'./01)23/,4".#5) 6',,'.)2"5%,%"&'(),")7.'/,)2/,%'&,5 B1&91F/ )*4546/3'!"#$"%&'789: !"#$"%&'!( )*+,-./01'2/03 ! ="#(:*"(/0&*%--9/#'2&"($)* !"#$%&#"'$()*+$,*-$(*-( ! !"#$"%&'(")*!"#$%"&'()&&*%'+!(,' $"#:97'.*.$(//%/0*".#)/012' ./(0$,,(12$3"+4(5(678*9-()39#$*-8 -*&& $+(',#"-.*.$(//%/0*

ImmunityBio — 39th Annual JP Morgan Healthcare Conference 2021 on 6ix